This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Malcolm Roberts, PhD
Principal Scientist at Eisai Limited


Malcolm Roberts was awarded his PhD from the Department of Biochemistry, University of Cambridge in 2004.  Immediately after graduation he joined the Japanese pharmaceutical company Eisai at their operational site in the UK.  His expertise is neurodegenerative diseases such as Alzheimer’s and Parkinson’s and he has led a number of drug discovery projects, both small and large molecule, throughout his career in industry.  Currently, Malcolm is a Principal Scientist within Eisai’s Neurology Business Group and with his team, he works closely with academic collaborators to validate novel drug targets and develop new therapeutic agents for testing in patients with neurodegenerative diseases.

Agenda Sessions

  • Chairperson’s Remarks

  • E2814: A High-affinity Antibody Targeting Tau for the Treatment of Alzheimer’s Disease